Sweden · Delayed Price · Currency is SEK Mendus AB Earnings Call Transcripts
Fiscal Year 2025
-
Positive phase II data in AML and ovarian cancer support broad positioning of vididencel, with new CML trials planned for 2026. Financing secured extends runway into 2027, and strategic focus shifts to align with evolving AML and CML treatment landscapes.
-
Positive long-term survival data in AML supports broader clinical development, with key trials in AML, CML, and ovarian cancer advancing. Cash runway extends into early 2026, with staff reductions offsetting higher trial costs.
-
Positive Phase II AML and early ovarian cancer trial data support broad potential for vididencel, with key patent granted and late-stage development progressing. Cash burn decreased year-over-year, and first GMP batches are expected before year-end.
-
Supportive regulatory feedback and clinical progress in AML with Vididencel, ongoing expansion of trials, and strengthened leadership with a new CMO. Q1 2025 saw an operating loss of SEK 30 million and a cash position of SEK 84.7 million, with cash reserves expected to last into 2026.
Fiscal Year 2024
-
Updated survival data in AML show durable benefit for vididencel, with phase III trial preparations and large-scale manufacturing on track. Cash runway extends to early 2026, supported by cost-saving and grants, while additional funding or partnership will be needed for late-stage development.
-
Opened first clinical centers for the CADENCE trial and advanced pivotal readiness for vididencel in AML. Financials show a Q3 net loss of SEK 23 million and a cash position of SEK 109.3 million, with cost efficiencies extending the cash runway. Multiple clinical milestones and data readouts are expected in the coming quarters.
-
Raised SEK 69 million, maintained a strong cash position, and advanced key clinical programs in AML, ovarian cancer, and soft tissue sarcoma. Proof of concept for vididencel in AML was confirmed, with pivotal trial preparations and major collaborations underway.